Hexahydrocannabinol (HHC) has garnered increasing attention in recent years as a novel cannabinoid. This comprehensive article examines the current state of research on HHC, analyzes existing studies, and identifies gaps in research.
The goal is to provide a thorough understanding of the scientific findings regarding HHC while also highlighting the need for further research.
Chemical Properties and Synthesis of HHC
HHC was first synthesized in 1940 by the American chemist Roger Adams. The compound is produced by hydrogenation of THC, whereby hydrogen molecules are incorporated into the THC structure.
This results in the saturation of the double bonds in the cyclohexenyl ring. Modern manufacturing methods often use CBD as a starting material, which is first converted into Δ8- or Δ9-THC and then hydrogenated.
Isomers and Their Significance
Studies on HHC have shown that the compound exists as a mixture of two diastereomers: 9α-HHC and 9β-HHC. Interestingly, these isomers exhibit different psychoactive properties, with 9β-HHC demonstrating a stronger effect and a higher affinity for cannabinoid receptors.
This finding underscores the complexity of HHC research and the need to closely examine the specific properties of each isomer.
Pharmacological Effects of HHC
Receptor Binding and Psychoactivity
Recent studies on HHC suggest that the compound binds to CB1 and CB2 receptors in a manner similar to THC, though with lower affinity. Preliminary animal studies show dose-dependent effects:
Low doses may have anxiolytic effects , while higher doses impair motor coordination. These findings are consistent with user reports describing euphoric states, sedation, or sensory enhancement.
Potential therapeutic applications
Some studies on HHC have yielded promising results regarding potential medical applications. For example, HHC analogs such as LYR-7 and LYR-8 show potential as cancer drugs by inhibiting cell proliferation and angiogenesis.
In addition, (9R)-HHC exhibits analgesic properties, suggesting a partially CB1-mediated psychotropic effect. These findings open up new avenues of research for the development of HHC-based therapeutics.
Photo by CHUTTERSNAP on Unsplash
What new studies are there on the psychoactive effects of HHC?
Current studies on the psychoactive effects of HHC (hexahydrocannabinol) remain limited, but some recent research findings provide important insights: A study published in 2024 examined the "activation of cannabinoid receptor 1 mediated by hexahydrocannabinol (HHC) and Δ9-tetrahydrocannabinol (Δ9-THC)"¹. This comparative analysis is crucial for understanding the specific psychoactive properties of HHC.Graziano et al. conducted in vivo studies that showed that both HHC diastereomers (9R-HHC and 9S-HHC) have effects on the central nervous system, albeit with lower potency compared to Δ9-THC.
The study suggested that 9R-HHC might be more potent than 9S-HHC, indicating a potential for addiction associated with this diastereomer. A 2023 study by Busardo et al. provided initial insights into the pharmacology, toxicology, and analysis of HHC as a new psychoactive substance.
Despite these new findings, experts such as Prof. Dr. Volker Auwärter emphasize that there are currently no valid studies on the short-term or long-term effects of HHC. However, the available data suggest that β-HHC, in particular, has psychoactive potential, while the cannabimimetic activity of α-HHC appears to be significantly lower. Laboratory studies in various animal models suggest that the effects of HHC are broadly similar to those of THC.
In rhesus monkeys, an intravenous dose of 1 mg/kg of 9β-HHC produced severe effects such as loss of activity, ataxia, and lack of response to external stimuli. It is important to emphasize that relevant dose-response studies in humans are currently lacking. The exact pharmacological and behavioral effects of HHC in humans have therefore not yet been fully elucidated.
What are the differences in the psychoactive effects of 9R-HHC and 9S-HHC?
Based on current studies and findings, there are significant differences in the psychoactive effects of 9R-HHC and 9S-HHC:
9R-HHC:
- Binds strongly to CB1 and CB2 receptors in the endocannabinoid system.
- Produces pronounced psychoactive effects, similar to delta-9 THC.
- It has about 75% of the potency of delta-9 THC.
- May cause euphoria, relaxation, and changes in perception.
- Actively interacts with the nervous system and induces psychoactive effects.
9S-HHC:
- Has a significantly lower affinity for cannabinoid receptors.
- Has little to no psychoactive effect.
- Does not significantly affect the receptors in the brain.
- Contributes little to the overall high in HHC products.
The ratio of 9R-HHC to 9S-HHC in an HHC product significantly determines its overall effect. Products with a higher proportion of 9R-HHC are generally considered to be more potent and to have a stronger psychoactive effect. It is important to note that, despite these findings, comprehensive clinical studies in humans are still lacking to fully understand the exact differences and long-term effects.
Toxicological aspects and safety concerns
Lack of long-term studies
A critical issue in HHC research is the lack of long-term studies on toxicity and safety. The German Federal Institute for Risk Assessment (BfR) warns of potentially high health risks, asthere is insufficient data on both acute and chronic toxicity. This knowledge gap poses a significant challenge for the risk assessment and regulation of HHC products.
Impurities and byproducts of synthesis
Studies on HHC have raised concerns about potential contaminants resulting from the synthesis process. These include palladium residues or incompletely hydrogenatedTHC derivatives.² These potential contaminants could pose additional health risks and underscore the need for strict quality controls in HHC production.
Hepatotoxicity and other side effects
An animal study published in 2024 demonstrated hepatotoxic effects following long-term exposure to HHC, although no clear dose-response relationship was observed. These findings highlight the need for further research into the liver toxicity and other potential long-term side effects of HHC.
Current research priorities and gaps
Comparative studies with other cannabinoids
A key focus of current studies on HHC is comparing its pharmacological properties with those of other cannabinoids. A study published in 2024 examined the "activation of cannabinoid receptor 1 mediated by hexahydrocannabinol (HHC) and Δ9-tetrahydrocannabinol (Δ9-THC)"2. Such comparative analyses are crucial for understanding the unique properties and potential benefits of HHC.
Studies on Bioavailability and Metabolism
Another important area of research concerns the bioavailability and metabolism of HHC in the human body. Studies on various routes of administration (oral, inhalation) and their effects on the absorption and duration of action of HHC are necessary to betterunderstand its pharmacological properties2.
Research gaps and future directions
Despite the growing number of studies on HHC, many questions remain unanswered. In particular, there is a lack of:
- Controlled human studies on psychoactivity and safety
- Long-term studies on chronic effects and the potential for dependence
- Studies on drug interactions
- Studies on genotoxicity and reproductive toxicology
These research gaps underscore the need for further comprehensive studies on HHC in order to fully assess its safety and potential therapeutic applications.
Regulatory Challenges and Consumer Protection
Legal gray area
HHC falls into a legal gray area in many countries because itis not explicitlycovered by the UN drug conventions.² This situation makes it difficult to regulate and control HHC products and can lead to safety risks for consumers.
Quality Control and Product Safety
Given the potential risks posed by contaminants and unknown long-term effects, experts recommend strict quality controls for HHC products. The BfR classifies foods containing HHC as "unsafe,"underscoring the need for regulatory measures5.
Future Research Directions for HHC
Therapeutic Potential of HHC
Future studies on HHC should focus on investigating its therapeutic potential, particularly in areas such as pain management and cancer treatment. The promising results regarding HHC analogs in cancer research provide a good starting point for furtherinvestigation1.
Improvement of synthesis methods
Optimizing HHC synthesis is an important area of research aimed at improving the purity and safety of the compound. Studies areneeded to develop more efficient and environmentally friendly production methods.³
Epidemiological studies
Given the increasing prevalence of HHC products, large-scale epidemiological studies are needed to assess patterns of use, the potential for abuse, and possible health effects in the general population.
What do the latest HHC studies say?
Research on hexahydrocannabinol (HHC) has made significant progress in recent years, yet many questions remain unanswered. While some studies on HHC have yielded promising results regarding potential therapeutic applications, others urge caution in light of possible health risks. The complexity of HHC isomers, the diversity of pharmacological effects, and the challenges in synthesis and quality control underscore the need for further comprehensive research. Future studies on HHC should focus on controlled human trials, long-term studies on safety and efficacy, and research into specific therapeutic applications. At the same time, close collaboration between researchers, regulatory authorities, and industry is necessary to ensure the safe development and use of HHC products.The dynamic developments in the field of cannabinoid research promise exciting insights for the future. HHC could prove to be a valuable addition to the therapeutic arsenal of cannabinoids, but there is still a long way to go. Continuous research and responsible handling of the findings are crucial to unlocking the full potential of HHC while ensuring consumer safety.
You might also be interested in these topics
Frequently Asked Questions
When was HHC first synthesized?
HHC was first synthesized in 1940 by the American chemist Roger Adams. The compound is formed by the hydrogenation of THC, a process in which hydrogen molecules are incorporated into the THC structure.
What is the difference between 9R-HHC and 9S-HHC?
9R-HHC binds strongly to CB1 and CB2 receptors and produces pronounced psychoactive effects, with approximately 75% of the potency of delta-9 THC. 9S-HHC has a significantly lower affinity and exhibits little to no psychoactive effect.
Are there any long-term studies on the safety of HHC?
No, a key concern is the lack of long-term studies on toxicity and safety. The BfR warns of potentially high health risks, as there is insufficient data on both acute and chronic toxicity.
What types of impurities can be found in HHC?
Studies have raised concerns about potential contaminants resulting from the synthesis process. These include palladium residues or incompletely hydrogenated THC derivatives, underscoring the need for strict quality controls.
Share:
Is HHC a drug? 9 facts you need to know
The Difference Between THC and HHC: 15 Facts for Cannabis Enthusiasts in 2025